BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 2, 2004
View Archived Issues
Money Raised Year To Date
Read More
Stock Winners and Losers For The Week
Read More
Underwriters' Performance on all Public Offerings Jan. 1 July 16, 2004: Full Credit to All Underwriters, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on all Public Offerings Jan. 1 - July 16, 2004: Full Credit to all Underwriters, Ranked by After-Market Performance*#
Read More
Underwriters' Performance on All Public Offerings from Jan. 1 to July 16, 2004: Full Credit to Lead Underwriter, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on All Public Offerings from Jan. 1 to July 16, 2004: Full Credit to Lead Underwriter, Ranked by After-Market Performance#
Read More
Underwriters' Performance on All IPOs from Jan. 1 to July 16, 2004: Full Credit to All Underwriters, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on All IPOs from Jan. 1 TO July 16, 2004: Full Credit to All Underwriters, Ranked by After-Market Performance#
Read More
Underwriters' Performance on All IPOs from Jan. 1 TO July 16, 2004: Full Credit to Lead Underwriter, Ranked by Gross Proceeds*
Read More
Underwriters' Performance on All IPOs from Jan. 1 to July 16, 2003: Full Credit to Lead Underwriter, Ranked by After-Market Performance#
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More
Fragment-Based Drug Discovery Drawing Still More Pharma Cash
Read More